Target intelligence / Profile preview

Epstein-Barr virus nuclear antigen 1 peptide-human leukocyte antigen complex (EBNA1 peptide-HLA complex)

Target
EBNA1 peptide-HLA complex
Molecular classification
Peptide-MHC complex, Receptor, Other
01

Overview

The Epstein-Barr virus nuclear antigen 1 peptide-human leukocyte antigen complex (EBNA1 peptide-HLA complex) is a major histocompatibility complex presenting a processed peptide epitope derived from the EBNA1 protein of the Epstein-Barr virus (EBV). EBNA1 is a multifunctional viral protein essential for the replication, segregation, and maintenance of the EBV episome during latent infection, and it is uniquely expressed in all EBV-associated malignancies, including nasopharyngeal carcinoma, Burkitt's lymphoma, Hodgkin's lymphoma, and EBV-positive gastric cancer. Although EBNA1 contains a glycine-alanine repeat (GAr) domain that inhibits its proteasomal degradation and limits classical MHC class I presentation, EBNA1-derived peptides are endogenously processed and presented on both HLA class I (e.g., HLA-A*02:01, HLA-B*35:01) and HLA class II (e.g., HLA-DP5, HLA-DR1) molecules. This complex serves as a highly specific therapeutic target for T-cell receptor-engineered T-cell (TCR-T) therapies (such as YT-E001), TCR-like monoclonal antibodies (such as clone E1), and TCR-like chimeric antigen receptor (CAR) T cells. These immunotherapies recognize the specific peptide-HLA conformation on the surface of EBV-infected or malignant cells, triggering targeted cell lysis via mechanisms like TCR-mediated cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC). However, targeting this complex presents challenges, including potential cross-reactivity with self-peptides (such as GlialCAM, which is implicated in the molecular mimicry driving multiple sclerosis), risk of cytokine release syndrome (CRS), and tumor immune evasion through HLA downregulation.

Other names
EBNA1 peptide-MHC complexEBNA1/HLA complexEBNA1-HLA complexEpstein-Barr virus nuclear antigen 1 peptide-MHC complexHLA-A*02:01/EBNA1 peptide complexHLA-DP5/EBNA1 peptide complex
02

Mechanism of action

Immunotherapies targeting the EBNA1 peptide-HLA complex act by binding specifically to the presented viral peptide in the groove of the HLA molecule. This binding triggers targeted cell lysis of EBV-infected or malignant cells through T-cell receptor (TCR)-mediated cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or chimeric antigen receptor (CAR)-mediated cytotoxicity.

03

Biological functions

Immune responseAntigen presentationOther
04

Disease associations

CancerInfectionNeurodegenerative diseaseOther
05

Safety considerations

On-target, off-tumor toxicity due to potential cross-reactivity with self-peptides (e.g., GlialCAM molecular mimicry in multiple sclerosis)Cytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)Tumor immune evasion via HLA downregulation or loss of antigen presentation
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

HLA-A*02:01 expressionHLA-DP5 expressionEBV DNA loadEBNA1 expressionAnti-EBNA1 IgG antibody levels

Beyond the preview

Go deeper on Epstein-Barr virus nuclear antigen 1 peptide-human leukocyte antigen complex (EBNA1 peptide-HLA complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epstein-Barr virus nuclear antigen 1 peptide-human leukocyte antigen complex (EBNA1 peptide-HLA complex).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call